# Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection

> **NCT06706310** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Chia Tai Tianqing Pharmaceutical Group Co., Ltd.** · enrollment: 116 (estimated)

## Conditions studied

- Chronic Hepatitis B

## Interventions

- **DRUG:** Placebo
- **DRUG:** TQA3334 Tablet
- **DRUG:** Nucleoside (acid) analogs (NAs)

## Key facts

- **NCT ID:** NCT06706310
- **Lead sponsor:** Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2024-12-04
- **Primary completion:** 2025-06-22
- **Final completion:** 2026-06
- **Target enrollment:** 116 (ESTIMATED)
- **Last updated:** 2025-11-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06706310

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06706310, "Evaluate TQ-A3334 Combined Nucleoside (Acid) Analogs in the First Treatment/Treatment of Chronic HBV Infection". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT06706310. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*